RTA 744 Injection in Patients With Leptomeningeal Disease
Status:
Terminated
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
1. The primary objectives of this study are:
1. To determine the tolerability of RTA 744 Injection in patients with leptomeningeal
disease (LMD) secondary to any type of primary tumor.
2. In a selected group of 6-10 patients who will receive RTA 744 at or near the
maximum tolerated dose (MTD), to characterize the multiple-dose pharmacokinetics of
RTA 744 in plasma and CSF.
2. The secondary objectives of this study are:
1. To document any potential antitumor activity of RTA 744 in this patient population.
2. To correlate pharmacokinetic information with clinical (efficacy and safety)
responses, as a possible help in selecting appropriate doses for later studies.